Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?

Arthritis Rheum. 2004 Apr;50(4):1040-50. doi: 10.1002/art.20164.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Arteriosclerosis / epidemiology
  • Arthritis, Juvenile / drug therapy
  • Arthritis, Juvenile / epidemiology
  • Etanercept
  • Heart Failure / drug therapy*
  • Heart Failure / epidemiology
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Infliximab
  • Prevalence
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept